Evidence map›Paper›PMID 32513967›Full record

ArticleProstate cancer and prostatic diseases2020

Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease.

Reith R Sarkar, Sunil H Patel, J Kellogg Parsons, Rishi Deka, Abhishek Kumar, John P Einck, Arno J Mundt, A Karim Kader, Christopher J Kane, Paul Riviere and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Reith R Sarkar *Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
Sunil H Patel *Veteran Affairs Healthcare, San Diego, CA, USA.
J Kellogg ParsonsDepartment of Urology, University of California San Diego, La Jolla, CA, 92093, USA. k0parsons@health.ucsd.edu.
Rishi DekaDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
Abhishek KumarDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
John P EinckDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
Arno J MundtDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
A Karim KaderDepartment of Urology, University of California San Diego, La Jolla, CA, 92093, USA.
Christopher J KaneDepartment of Urology, University of California San Diego, La Jolla, CA, 92093, USA.
Paul RiviereDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0001-7966-3090
Rana McKayDivision of Hematology-Oncology, Department of Internal Medicine, University of California San Diego, La Jolla, CA, 92093, USA.
James D MurphyDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
Brent S RoseDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0002-3197-9552
University of California San Diego · USUC San Diego Health System · US

Funding

UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
UC San Diego Clinical and Translational Research InstituteTL1TR001443 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2019
$3.4M
NCATS NIH HHS KL2 TR001444NCATS NIH HHS TL1 TR001443NIH HHS TL1TR001443
6 · The paper itself

Abstract

backgroundThe safety of testosterone therapy (TT) after definitive treatment for localized prostate cancer remains undefined. We analyzed the risks of biochemical recurrence and mortality in men receiving TT after treatment for localized prostate cancer.

methodsCohort analysis using the national US Veterans Affairs Informatics and Computing Infrastructure. We identified 69,984 patients with localized prostate cancer diagnosed from 2001 to 2015 treated with surgery or radiation. We coded receipt of TT after treatment as a time-dependent covariate; used the National Death Index to identify cause of death; and defined biochemical recurrence as PSA > 0.2 ng/mL after surgery and nadir + 2 ng/mL after radiation. We analyzed recurrence and mortality using cumulative incidence curves, Fine-Gray competing risk regression, and Cox regression.

resultsThis cohort included 28,651 surgery patients and 41,333 radiation patients, of whom 469 (1.64%) and 543 (1.31%), respectively, received TT with a median follow-up of 6.95 years. Comparing testosterone users to nonusers, there were no between-group differences in biochemical recurrence, prostate cancer-specific mortality, or overall mortality after surgery [hazard ratios (HR): 1.07; HR: 0.72 (p = 0.43); and HR: 1.11 (p = 0.43), respectively] or radiation [HR: 1.07; HR: 1.02 (p = 0.95); and HR: 1.02 (p = 0.86), respectively]. Limitations included lack of detailed data on TT duration and serum testosterone concentrations.

conclusionsIn this multi-ethnic national cohort, TT did not increase the risks of biochemical recurrence or prostate cancer-specific or overall mortality after surgery or radiation. These data suggest that TT is safe in appropriate men after definitive treatment of localized prostate cancer.

Indexed as

AgedAndrogensCombined Modality TherapyDatabases, FactualFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Recurrence, LocalProstatectomyProstatic NeoplasmsRadiotherapyRetrospective StudiesSurvival RateTestosteroneAndrogensTestosterone

Identifiers

PMID32513967
PMCPMC11220914
OpenAlexW3033236681

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.